| Connors et al. (1996) |
1,016 patients with severe exacerbation |
43% |
FEV1, BMI, Age, PaO2 |
| Almagro et al. (2002) |
135 patients after severe exacerbation |
22% |
Age, women, SGRQ, previous severe exacerbations, PaCO2 |
| Groenewegen, Schols & Wouters (2003) |
171 patients with severe exacerbation |
23% |
PaCO2, Age |
| Kim, Clark & Camargo (2006) |
482 patients after ED visit |
23% |
Age, comorbidities, previous severe exacerbations |
| Coleta et al. (2008) |
78 patients using LTOT |
15.4% |
BDI, PaO2, PaCO2, SGRQ |
| Fan et al. (2007) |
603 patients |
7.5% |
|
| Gershon et al. (2010) |
>30,000 patients from Canadian register |
4.3–5.7% |
|
| Piquet et al. (2013) |
1,824 patients with severe exacerbation |
16.8% |
Age, lower BMI, lung cancer, cardiovascular comorbidity, previous severe exacerbations, LTOT |
| Ho et al. (2014) |
4,029 patients with severe exacerbations |
22% |
Age, comorbidity |
| Müllerova et al. (2015) |
2,138 patients |
5.1% in patients without severe exacerbation and 14.6% in patients with severe exacerbation |
Severe exacerbations, longer hospital stay |
